A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setti-Reference-Cited by-同舟云学术

A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setti

Published:2018-03-22 Issue:5 Volume:19 Page:1007-1013
ISSN:1399-543X
Container-title:Pediatric Diabetes
language:en
Short-container-title:Pediatr Diabetes

Author:

Deeb Larry C¹,Dulude Hélène²,Guzman Cristina B³,Zhang Shuyu⁴,Reiner Barry J⁵,Piché Claude A²,Pradhan Sheetal⁶,Zhang Xiaotian Michelle⁷^ORCID

Affiliation:

1. Department of Pediatrics, Florida State University College of Medicine; Tallahassee Florida

2. Clinical Development, Locemia Solutions; Montreal Québec Canada

3. Medical Development, Diabetes Business Unit, Formerly Eli Lilly and Company; Indianapolis Indiana

4. Statistics, Eli Lilly and Company; Indianapolis Indiana

5. Clinical Development, Pediatric Endocrine Private Practice; Baltimore Maryland

6. Global Scientific Communications, Diabetes Business Unit, Eli Lilly Services India Pvt. Ltd.; Bangalore Karnataka India

7. Medical Development, Diabetes Business Unit, Eli Lilly Canada Inc.; Toronto Ontario Canada

Funder

Eli Lilly and Company, Indianapolis, IN, USA

Locemia Solutions, Montreal, QC, Canada

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology, and Child Health,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/pedi.12668/fullpdf

Reference18 articles.

1. Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach;Kedia;Diabetes Metab Syndr Obes,2011

2. Management of hypoglycemia in children and adolescents with type 1 diabetes mellitus;McGill;Curr Diab Rep,2016

3. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of diabetes;International Hypoglycemia Study Group;Diabetes Care,2017

4. Assessment and management of hypoglycemia in children and adolescents with diabetes;Ly;Pediatr Diabetes,2014

5. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society;Seaquist;Diabetes Care,2013

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Intranasal and Injectable Glucagon Administration Among Pediatric Population Responders;Diabetes Technology & Therapeutics;2023-11-01

2. Nasal glucagon is safe and effective in children and adolescents with type 1 diabetes: A real‐world prospective cohort study;Diabetes, Obesity and Metabolism;2023-10-22

3. Emerging Adult and Caregiver Psychosocial Experiences with Severe Hypoglycemic Events and the Perceived Impact of Nasal Glucagon: A Cross-Sectional Study;Diabetes Therapy;2023-06-02

4. Type 1 diabetes;The Lancet;2023-06

5. Dose Rationale of Nasal Glucagon in Japanese Pediatric Patients with Diabetes Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation;Pediatric Drugs;2023-03-27